Lv5
920 积分 2022-08-10 加入
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
3小时前
已关闭
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
20天前
已关闭
膀胱神经内分泌癌的研究进展
5个月前
已完结
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
6个月前
已完结
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
6个月前
已关闭
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
6个月前
已完结
The efficacy and safety of cadonilimab after first anti-PD-1 failure in the treatment of recurrent endometrial and cervical carcinoma: A retrospective, real-world study
6个月前
已完结
Baseline, Early Changes, and Residual Albuminuria: Post-hoc Analysis of a Clinical Trial of Dapagliflozin in Chronic Kidney Disease
8个月前
已关闭
baseline, early changes, and residual albuminuria: post-hoc analysis of a clinical trial of dapagliflozin in chronic kidney disease
8个月前
已关闭
皖公网安备34019202002308
